HC Wainwright reissued their buy rating on shares of Mediwound (NASDAQ:MDWD) in a research report released on Friday, AnalystRatings.com reports. They currently have a $5.50 price objective on the biopharmaceutical company’s stock.

A number of other research firms have also weighed in on MDWD. ValuEngine raised Mediwound from a sell rating to a hold rating in a report on Thursday, August 1st. Zacks Investment Research raised Mediwound from a hold rating to a buy rating and set a $3.25 target price for the company in a report on Wednesday, October 30th. Finally, Oppenheimer reduced their target price on Mediwound from $15.00 to $7.00 and set an outperform rating for the company in a report on Wednesday, August 14th.

Mediwound stock traded up $0.07 during midday trading on Friday, reaching $3.08. The stock had a trading volume of 325 shares, compared to its average volume of 40,380. Mediwound has a 12 month low of $2.55 and a 12 month high of $6.09. The firm’s 50-day moving average price is $2.95 and its 200 day moving average price is $3.40. The firm has a market capitalization of $82.89 million, a PE ratio of -6.29 and a beta of 0.48. The company has a quick ratio of 3.52, a current ratio of 3.65 and a debt-to-equity ratio of 0.11.

Mediwound (NASDAQ:MDWD) last announced its quarterly earnings data on Thursday, November 14th. The biopharmaceutical company reported ($0.01) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.13) by $0.12. The business had revenue of $5.14 million for the quarter, compared to analysts’ expectations of $2.67 million. Mediwound had a negative return on equity of 94.57% and a net margin of 69.50%. Equities research analysts expect that Mediwound will post -0.57 EPS for the current year.

A number of hedge funds have recently bought and sold shares of the business. California Public Employees Retirement System grew its holdings in Mediwound by 5.8% during the 3rd quarter. California Public Employees Retirement System now owns 211,500 shares of the biopharmaceutical company’s stock valued at $670,000 after buying an additional 11,600 shares in the last quarter. ARK Investment Management LLC purchased a new position in shares of Mediwound during the second quarter worth about $325,000. Oppenheimer & Co. Inc. grew its holdings in shares of Mediwound by 11.0% during the third quarter. Oppenheimer & Co. Inc. now owns 48,600 shares of the biopharmaceutical company’s stock worth $156,000 after purchasing an additional 4,800 shares in the last quarter. Sargent Investment Group LLC grew its holdings in shares of Mediwound by 63.8% during the third quarter. Sargent Investment Group LLC now owns 47,500 shares of the biopharmaceutical company’s stock worth $152,000 after purchasing an additional 18,500 shares in the last quarter. Finally, Marshall Wace LLP purchased a new position in shares of Mediwound during the first quarter worth about $93,000. 29.04% of the stock is owned by institutional investors and hedge funds.

About Mediwound

MediWound Ltd., an integrated biopharmaceutical company, focuses on developing, manufacturing, and commercializing novel therapeutics products to address unmet needs. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns in the European Union, Israel, and Argentina.

Featured Article: Why do companies issue monthly dividends?

Receive News & Ratings for Mediwound Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mediwound and related companies with MarketBeat.com's FREE daily email newsletter.